Case Report
-c]. Bronchoscopy and bronchoalveolar lavage (BAL) were done in all patients and subjected to special stain (Gomori methenamine silver [GMS]), which confirmed PCP [ Figure 3 ]. Patient 1 was started on TMP-SMX (Dose: TMP: 15-20 mg/kg/day and SMX: 75-100 mg/kg/day); he developed severe leukopenia; the drug was discontinued and was started on oral C + P. Patients 2 and 3 had renal insufficiency. They were treated with oral clindamycin (600 mg, thrice daily) + primaquine (30 mg, once daily) for 21 days as the first-line therapy. Adjunctive prednisolone was also given for 3 weeks; 40 mg twice daily for 5 days, followed by 40 mg daily for 5 days and then 20 mg daily for 11 days. The dose of mycophenolate mofetil was also reduced.
All three patients tolerated the medications and had complete resolution of symptoms in 3 weeks. Clinical characteristics after treatment are summarized in Table 3 . Imaging of chest showed complete resolution of lesions [ Figure 4a -c]. No adverse effects were noted with C + P combination therapy.
discussiOn
PCP is an opportunistic infection that typically presents in the first 6 months after renal transplantation, with fever, nonproductive cough, effort intolerance, low oxygen saturation, and diffuse interstitial infiltrates on radiograph of the chest. All three of our patients had fever and cough; two of them had low oxygen saturation on presentation. Two patients 
Risk factors for PCP include use of ATG, corticosteroids, m y c o p h e n o l a t e m o f e t i l , c a l c i n e u r i n i n h i b i t o r s , cytomegalovirus disease, low CD4+ T cell counts, neutropenia, and most importantly exposure to patients with PCP. ATG induction has been reported to be the highest risk factor for PCP, [2] as seen in our first patient who developed infection in spite of receiving PCP prophylaxis. In our institute, we give PCP prophylaxis with TMP-SMX for all kidney transplant recipients for the first 6 months after renal transplantation. Other risk factors include use of antirejection therapy, [3] as seen in our second patient, who had received three doses of intravenous methyl prednisolone.
HRCT scans are more sensitive than radiograph of the chest and may show ground-glass opacities with sparing of lung periphery; [4] this was noted in our cases, where two patients had near-normal X-ray chest and HRCT chest was clearly abnormal. BAL microscopy and staining is a highly sensitive method of diagnosing PCP and has a yield of 80%. [2] All the three cases underwent BAL with special staining with GMS stain, which can identify cell wall of the cysts. [2] In all three cases, GMS stain was positive and diagnosis was established by demonstrating the organism; polymerase chain reaction (PCR) was positive for Pneumocystis jirovecii. PCR with sputum and BAL fluid samples have a high sensitivity and specificity for the detection of the organism, but lacks utility in diagnosing PCP, as PCR cannot differentiate colonization from infection. However, PCR has a negative predictive value of 100%. [1] TMP-SMX is the first-line agent and is quoted as the drug of choice. [5] No agent has been shown to have a superior outcome. Patient 1 was started on therapeutic dose of TMP-SMX; there was a fall in total leukocyte count, TMP-SMX was stopped, and he was started on oral C + P. Leukopenia is a known complication of TMP-SMX, risk is higher when used in combination with an antimetabolite; TMP-SMX causes a dose-dependent leukopenia, [6] and a high dose of TMP-SMX (TMP: 15-20 mg/kg/day and SMX: 75-100 mg/kg/day) is recommended for treating PCP; however, there is no reported risk of leukopenia with C + P. TMP-SMX is associated with thrombocytopenia as well; generation of antibodies to glycoprotein IIb/IIIa complex on platelets can cause immune thrombocytopenia which is most commonly seen in within 1 st week of treatment and is reversible on stopping the drug, [6] there is no risk for thrombocytopenia with C + P. Hyperkalemia is also seen in 6% of patients receiving TMP-SMX; [6] however, incidence can go up to 50% in those with graft dysfunction. [7] In Patient 2, there was moderate renal failure (serum creatinine: 4.56 mg%), renal dose modification is needed for TMP-SMX and requires drug level monitoring. [6] Therefore, TMP-SMX was not considered and he was started on oral C + P. There is no need for dose modification and drug level monitoring for C + P. Patient 3 also had graft dysfunction and was started on oral C + P. There is a consensus for adjunctive steroid therapy in HIV-infected patients, [8] the dose recommended was used in our patients for 3 weeks, which they tolerated well.
All three patients showed clinical improvement and recovered completely. Oral therapy with C + P is adequate because the oral bioavailability of clindamycin is 90% and primaquine is 96%. Moreover, primaquine is not available in parenteral form; however, we agree parenteral clindamycin can be considered to have an edge over the oral regimen. Graft functions showed an improvement. No adverse effects of the drugs were noted. There are no drug interactions of C + P with tacrolimus and mycophenolate mofetil. Most of the data on C + P for treatment of PCP comes from HIV-infected patients. The first study done exclusively in renal transplant recipients to assess TMP-SMX versus C + P for treatment of PCP was reported in 2014. [9] The failure rate of TMP-SMX was more than C + P group, and half of the treatment failure in TMP-SMX group were attributed to adverse drug effects; no adverse drug effects were seen in the C + P group. [9] An Indian study also reported, adverse effects of TMP-SMX was seen in 44% of patients; they were eventually switched over to C+P; [7] the authors reported that superiority of TMP-SMX in the treatment of PCP compared to C + P is marginal. [7, 9] cOnclusiOn PCP in kidney transplant recipients can be safely and effectively treated with C + P, without any major drug-related side effects. There is need for further studies to conclude if C + P is noninferior to TMP-SMX in renal transplant recipients with graft dysfunction.
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